Medtronic stock holds firm as sales and EPS beat estimates

Quarter numbers still matter

Medtronic plc (IE00BTN1Y115) is trading with a market value of $115.77 billion on August 18, 2026, and the most recent cited session shows the shares around $90.44 to $92.59. The latest reported quarter delivered $9.81 billion in revenue and $1.55 in adjusted EPS, both above the $9.62 billion and $1.54 consensus figures.

That combination gives the stock a cleaner setup than a simple defensive-healthcare label suggests. Revenue was up 9.9% year over year, while the same period last year produced $1.62 in EPS, which frames the current quarter as a volume-and-profit rebound rather than a one-line beat.

Guidance stays in view

The same earnings update set FY 2027 EPS guidance at $5.90 to $6.00, while analysts currently center on $5.94 for the fiscal year. In the same body of cited data, the company also posted a net margin of 13.20% and return on equity of 14.51%.

For investors, the comparison that stands out is simple: a $0.01 EPS beat on $9.81 billion of sales is modest, but it came with 9.9% revenue growth and a forward range that still leaves room for execution. The stock's 52-week span of $73.31 to $106.33 keeps the current quote inside a wide trading band.

Consensus stays constructive

MarketBeat's current summary puts Medtronic at a consensus rating of Moderate Buy with an average target of $98.83, while another same-day market page shows a dividend yield of 3.11%. That places the shares in a familiar large-cap income profile, but with the quarterly growth rate now doing more of the work.

How the business earns

Medtronic's core business spans devices in cardiovascular, neuroscience and medical-surgical care, with recurrent demand from hospitals and procedure volumes supporting the model. The current quarter's $9.81 billion in revenue and 13.20% net margin show why the company remains a scale player rather than a single-product story.

Shares and valuation

As of August 18, 2026, the stock has been quoted at $90.44 and $92.59 on cited market pages, with market capitalization reported at $115.77 billion and $118.52 billion. That valuation range keeps Medtronic in the upper tier of global med-tech and leaves the next session focused on whether the market prices more weight into the $5.90 to $6.00 EPS outlook.

Fact box

Company: Medtronic plc

ISIN: IE00BTN1Y115

Ticker: MDT

Exchange: NYSE

Market cap: $115.77 billion to $118.52 billion

Sector / Industry: Health Care / Medical Devices

Index membership: S&P 500

More on Medtronic stock

Medtronic sells implantable and procedural products across cardiovascular, neuroscience, medical surgical and diabetes-linked care. The portfolio matters because it spreads revenue across hospital channels and makes the company less dependent on any single procedure line.

Medtronic stock at a glance

Medtronic stock is quoted in a broad $73.31 to $106.33 52-week range, with the latest cited market cap above $115 billion and a dividend yield of 3.11%. The current setup leaves the $98.83 consensus target and the $5.90 to $6.00 EPS guide as the next two reference points for the shares.